CytoGenix, Inc.
Genetic therapy in the 21st century promises to provide a dramatic change from treating symptoms to eliminating disease. CytoGenix, Inc. (CYGX), is a genomics and biopharmaceutical company that is pursuing research, development, and commercialization of their patented single-strand DNA (ssDNA) Sequence Expression Technology. This technology is focused on treatments for the heart, cancer, dermatological and viral diseases to ultimately improve the health and well being of humans and food animals. It may well be that many previously incurable diseases will be cured through the gene therapy employed by CytoGenix, Inc.
CytoGenix, Inc's technology will serve to enable the hundreds of other genomics companies who are developing thousands of gene sequences to complete and get approval for their therapeutic products. This is their market base opportunity. The Company is marketing laboratory tool kits as well as developing topical therapies that utilize this technology. They are also pursuing licensing opportunities with prominent biopharmaceutical and genomic companies, and they have Sponsored Research Agreements with major academic institutions.
To understand the Company technology, we must understand that disease processes result from the production of proteins from DNA that is either mutated or altered by pathogens (viruses). Much of genomic medicine focuses on preventing the production of these harmful proteins or interfering with their function. CytoGenix, Inc's technology is simple and elegant-inhibit protein production by blocking the translation of the messenger. Our technology allows cells to mass-produce DNA which binds to the messenger, thereby preventing the molecular mechanism that produces harmful proteins. Our technology could conceivably target a virally infected or a cancer cell with exquisite precision.
Please keep in mind the following.
Approximately 90% of the US population has some form of Herpes/Shingles.
There are thousands of cases of Cervical Cancer reported annually in the US.
How many Americans suffer from Lymphoma and Melanoma?
And what about Kaposi Sarcoma?
Cytogenix technology is applicable to virtually all diseases.
Until now, other companies have been trying to penetrate cells with single strands of DNA by flooding the system and hoping they cross the cell membrane and get into specific cells – a crude, random process. Even if the synthetic DNA penetrates the cell, insufficient levels of oligos accumulate inside the cell to be of any significant therapeutic value. Without risking toxicity and other harmful side effects, and to target specific cells with enough DNA to provide therapeutic value, the oligos must be produced inside the cell in sufficient quantities to be effective.
CytoGenix, Inc. has the proprietary Platform ssDNA Expression Technology to do just that!
Recently the share value of CytoGenix, Inc (CYGX) has been trading in the range of $.20. The company has no long-term debt, and has a market target price of $1.00 over the next twelve months. It is the opinion of the editors of TheHamptonReport.com that you should investigate this company further. This may offer an opportune time to place a few shares in your portfolio.
For more information regarding this unique company, and to review other company reports, please click here to go to the company website.
TheHamptonReport.com produces this report at the request of CytoGenix, Inc., and hereby expresses that neither it nor its employees, associates, assigns, or related parties have any interest in the company in the form of stock ownership. Rather, CytoGenix, Inc has paid a fee of $2500 to the owners of TheHamptonReport.com for producing this report. This report is not meant to be a recommendation to purchase securities, but instead only offer information on a public company, with the understanding that each individual reader is responsible in the determination as to purchase shares in this company and to whether this company may fit their portfolio requirements.
The Hampton Report newsletter is an independent electronic publication committed to providing its readers with information on selected publicly traded companies, and is paid to represent the companies shown on this web site. Nothing on this web site should be construed as investment advice. This profile is not a solicitation to buy or sell, and this does not purport to be a complete analysis of the company mentioned. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible. All statements and expressions are the sole opinions of the editors and are subject to change without notice. The opinions and statements in this publication do not necessarily reflect the position of the company being evaluated. While we believe all sources of information to be factual and reliable, The Hampton Report does not represent or guarantee the accuracy or completeness of any information represented on this web site or its publications. Information reported here is subject to change at any time, and The Hampton Report does not accept any obligation to provide updates to this report. The editor, members of the editor's family, and/or entities with which they are affiliated, may personally own stock in and have other financial dealings with the companies who appear in the publication. The Hampton Report critiques may contain forward-looking statements relating to the expected capabilities of the companies mentioned herein.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements in this newsletter regarding any reported companies business that are not historical facts are ``forward-looking statements'' that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ``Risk Factors'' in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF The Hampton Report.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at http://www.sec.gov/ and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com/ . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.
